TEVA一天跌了24%

mikeon88 發表於 2017-8-4 06:23  

一天跌了24%，真可怕！



duwa 發表於 2017-8-4 10:19  

Here's Why Teva Pharmaceutical Industries Ltd (ADR) Is Sinking Like a StoneShares plunge after the company reports dreadful second-quarter results and slashes its dividend payment.Brian Feroldi (TMFTypeoh)

Aug 3, 2017 at 2:35PM

What happenedIn response to reporting rough second-quarter results, shares of Teva Pharmaceutical Industries (NYSE:TEVA), a leading provider of generic drugs, dropped 24% as of 1:15 p.m. EDT on Thursday.

So whatHere's a review of the key takeaways from the company's second-quarter results:

Revenue jumped 13% to $5.68 billion, thanks largely to the inclusion of the Actavis Generics business that was acquired from Allergan (NYSE:AGN) last August. On a currency-neutral basis, this figure rose 17% year over year, but it came up shy of the $5.72 billion in revenue that Wall Street had expected.併購沒有綜效

Teva's U.S. generic business is facing major pricing and volume pressure due to consolidation among its customers and increased competition.

Specialty revenue dropped 9% during the quarter. While sales of many specialty drugs were weak, sales of multiple-sclerosis treatment Copaxone, the company's top-selling drug, fell 10% to $1.0 billion and were a major source of the overall decline.學名藥競爭激烈

Adjusted gross margin plunged 570 basis points when compared to the year-ago period.利潤下跌

A goodwill impairment charge of $6.1 billion was recorded during the quarter because of "market dynamics of the U.S. generics unit." That charge drove a GAAP (generally accepted accounting principles) net loss of $6 billion for the quarter.併購產生嚴重商譽減損

Adjusted net income fell 20% to $1.0 billion, or $1.02 per share, a figure that also fell short of the $1.06 that market-watchers had predicted.

An interim dividend of $0.085 per share was declared. This represents a cut of 75% when compared to last year.股息下降

The lower-than-hoped for results also caused management to pull back on its guidance for the year. The company now expects adjusted full-year revenue to land between $22.8 billion and $23.2 billion. That's down from its prior outlook of $23.8 billion to $24.5 billion.經營階級預測失準

The adjusted figure for earnings per share was taken down a notch, too. The new range is $4.30 to $4.50, which is down from the prior outlook of $4.90 to $5.30.

Given the disappointing quarterly results, slashed dividend, difficult operating conditions, and lowered guidance, it is easy to understand why traders are mauling the company's stock today.

通路優勢 不明

專利優勢 無

自主技術優勢 無 都是併購

競爭優勢 只剩規模經濟
管理優勢 無 併購無綜效  結論 便宜價可能forever